130 related articles for article (PubMed ID: 23682029)
1. Jump-starting the T cells in CLL.
Johnston JB
Blood; 2013 May; 121(20):4016-7. PubMed ID: 23682029
[TBL] [Abstract][Full Text] [Related]
2. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL).
Shanafelt TD; Ramsay AG; Zent CS; Leis JF; Tun HW; Call TG; LaPlant B; Bowen D; Pettinger A; Jelinek DF; Hanson CA; Kay NE
Blood; 2013 May; 121(20):4137-41. PubMed ID: 23493782
[TBL] [Abstract][Full Text] [Related]
3. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
[TBL] [Abstract][Full Text] [Related]
4. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
5. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.
Ramsay AG; Johnson AJ; Lee AM; Gorgün G; Le Dieu R; Blum W; Byrd JC; Gribben JG
J Clin Invest; 2008 Jul; 118(7):2427-37. PubMed ID: 18551193
[TBL] [Abstract][Full Text] [Related]
6. Treating chronic lymphocytic leukemia with thalidomide and lenalidomide.
Giannopoulos K; Mertens D; Stilgenbauer S
Expert Opin Pharmacother; 2011 Dec; 12(18):2857-64. PubMed ID: 22098228
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide and chronic lymphocytic leukemia.
González-Rodríguez AP; Payer AR; Acebes-Huerta A; Huergo-Zapico L; Villa-Alvarez M; Gonzalez-García E; Gonzalez S
Biomed Res Int; 2013; 2013():932010. PubMed ID: 24163824
[TBL] [Abstract][Full Text] [Related]
8. Immune reconstitution in chronic lymphocytic leukemia.
Riches JC; Ramsay AG; Gribben JG
Curr Hematol Malig Rep; 2012 Mar; 7(1):13-20. PubMed ID: 22231031
[TBL] [Abstract][Full Text] [Related]
9. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.
Winqvist M; Mozaffari F; Palma M; Eketorp Sylvan S; Hansson L; Mellstedt H; Österborg A; Lundin J
Cancer Immunol Immunother; 2017 Jan; 66(1):91-102. PubMed ID: 27815572
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in CLL: what is the optimal dose?
Wendtner CM
Clin Adv Hematol Oncol; 2011 Mar; 9(3):220-4. PubMed ID: 21475128
[No Abstract] [Full Text] [Related]
11. An update on current and prospective immunotherapies for chronic lymphocytic leukemia.
Emole JN; Locke FL; Pinilla-Ibarz J
Immunotherapy; 2015; 7(4):455-66. PubMed ID: 25917633
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients.
Palma M; Hansson L; Mulder TA; Adamson L; Näsman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Österborg A; Mellstedt H
Eur J Haematol; 2018 Jul; 101(1):68-77. PubMed ID: 29569742
[TBL] [Abstract][Full Text] [Related]
13. [Application of lenalidomide in chronic lymphocytic leukemia].
Lei W; Zhou KS; Li YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):565-8. PubMed ID: 24763044
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia.
Chavez JC; Piris-Villaespesa M; Dalia S; Powers J; Turba E; Nodzon L; Komrokji R; Sokol L; Locke FL; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Pinilla-Ibarz J
Leuk Res; 2016 Aug; 47():78-83. PubMed ID: 27285853
[TBL] [Abstract][Full Text] [Related]
15. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater AP; Tonino SH; Egle A; Ramsay AG
Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
[TBL] [Abstract][Full Text] [Related]
16. Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
Mato AR; Foon KA; Feldman T; Schuster SJ; Svoboda J; Chow KF; Valentinetti M; Mrkulic M; Azzollini K; Gadaleta G; Bhattacharyya PK; Zenreich J; Pascual LN; Yannotti K; Kdiry S; Howlett C; Strelec L; Porter D; Bejot C; Goy A
Am J Hematol; 2015 Jun; 90(6):487-92. PubMed ID: 25691474
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Mauro FR; Carella AM; Molica S; Paoloni F; Liberati AM; Zaja F; Belsito V; Cortellezzi A; Rizzi R; Tosi P; Spriano M; Ferretti A; Nanni M; Marinelli M; De Propris MS; Orlando SM; Vignetti M; Cuneo A; Guarini AR; Foà R
Leuk Lymphoma; 2017 Jul; 58(7):1640-1647. PubMed ID: 27881039
[TBL] [Abstract][Full Text] [Related]
18. Immunomodulatory drugs in chronic lymphocytic leukemia: a new treatment paradigm.
Molica S
Leuk Lymphoma; 2007 May; 48(5):866-9. PubMed ID: 17487728
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia.
Gassner FJ; Zaborsky N; Neureiter D; Huemer M; Melchardt T; Egle A; Rebhandl S; Catakovic K; Hartmann TN; Greil R; Geisberger R
Haematologica; 2014 May; 99(5):67-9. PubMed ID: 24561794
[No Abstract] [Full Text] [Related]
20. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]